Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 1998

View Archived Issues

Evaluation of the analgesic potential of 1,2,6-IP3

Recombinant methioninase shows clinical efficacy in depleting serum methionine

Neurocrine Biosciences reveals new technology

Evaluation of anti-IgE therapy in patients with seasonal allergic rhinitis

The Liposome Company: FY 1997 highlights

Sponge-derived natural product shows promise as a new cancer therapeutic

Muscarinic cholinergic agents from American Home

Pharmacyclics: Q2 1998 highlights

CoCensys: Q4 and FY 1997 highlights

First corticosteroid dry powder inhaler launched in the U.S.

Floxin Otic launched in U.S.

CellPro to begin clinical evaluation of B-Cell Depletion System

Celgene: Q4 and year-end 1997 highlights

CPMP recommends European approval of Exelon

Termination of merger discussions between SKB and Glaxo Wellcome

Perkin-Elmer and PerSeptive Biosystems complete merger

Flobufen update

Positive phase I results reported for TCAR product for MS

New herpes collaboration between Astra and Medivir

Apollo licenses technologies from U. of Florida

Quinolone HIV integrase inhibitors prepared at Warner-Lambert

First potent and selective CB2 receptor antagonist developed at Sanofi

DBD meets with FDA to discuss dibromodulcitol progress

Abbott will market Orion's calcium sensitizer levosimendan

Diatide issued approvable letter for AcuTect by FDA

Diversa receives NCI grant for pharmaceutical research

PI-88 one step closer to clinical testing

UCSF receives green light to develop new breast cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...